FDA Clearance Tracker · K221326
Nova Allegro HbA1c Assay, Nova Allegro Analyzer
Last checked: Nov 20, 2026Latest source record: Nov 22, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Nov 22, 2024
Substantially Equivalent
Time to decision
931 days
Received May 6, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K221326
- Device name
- Nova Allegro HbA1c Assay, Nova Allegro Analyzer
- Applicant
- Nova Biomedical Corporation
- Applicant location
- Walham, MA
- Received
- May 6, 2022
- Decided
- Nov 22, 2024
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device type
- Assay, Glycosylated Hemoglobin (LCP)
- Device class
- Class II
- Regulation
- 21 CFR 864.7470
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LCP. The earliest in FDA's data is K780819, decided Nov 7, 1978.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K221326
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Nova Biomedical Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K251281 · Decided Jan 21, 2026 · 272 days after receipt
Device type: Creatinine Test System For At Home Prescription Use (SHB) · Laboratory Medicine & Pathology
K252206 · Decided Jan 9, 2026 · 179 days after receipt
Device type: Alkaline Picrate, Colorimetry, Creatinine (CGX) · Laboratory Medicine & Pathology
K221813 · Decided Nov 19, 2024 · 881 days after receipt
Device type: Alkaline Picrate, Colorimetry, Creatinine (CGX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.